Viewpoints
Please check back later for more content.
Advertisement
Advertisement
Trending on Modern Retina
1
Ocugen completes dosing early in phase 2/3 GARDian3 trial for Stargardt disease
2
FDA expands faricimab label to include treatment of macular edema secondary to retinal vein occlusion beyond 6 months
3
Tattoo-associated uveitis: An emerging eye health challenge
4
OLN324 shows comparable vision gains, potential durability advantage vs faricimab in phase 1b wAMD, DME study
5